Treatment with etomoxir significantly decreased Ki-67 and increased CPT1 expression in HSJD-GBM-001 tumors (p < 0.05, p = 0.0001, 2-way ANOVA, respectively), and decreased SLC22A5 expression in U87 tumors (p < 0.05, 2-way ANOVA), Figure 5c. This evidence concerns the gene CPT2 and glioblastoma.